

CLAIMS

What is claimed is:

- Sub C1
1. A method of modulating Type 1 and Type 2 response in activated T cells of a human patient comprising administering ribavirin to the T cells in a dosage which promotes the Type 1 response and suppresses the Type 2 response.
 2. The method of claim 1 wherein the amount of ribavirin added provides a concentration of about 0.25 - 6.7 µg/ml in a medium supporting the lymphocytes.
 3. A method of treating a patient having a disease which includes a viral component and a non-viral component, the non-viral component being characterized by reduced Type 1 levels and increased Type 2 levels in activated T-lymphocytes, comprising administering ribavirin to the patient under a protocol sufficient to promote the Type 1 response and suppress the Type 2 response.
 4. The method of claim 3 further comprising adding interferon alpha to the lymphocytes.
 5. A method of inhibiting a virus by growing a virus in an environment having lymphocytes which produce Type 1 and Type 2 cytokine responses, and adding ribavirin to the environment in a concentration which increases the Type 1 response and suppresses the Type 2 response.
 6. The method of claim 5 wherein the virus comprises Hepatitis C.
- Sub C2
- Sub C3
- add C1
- add C4